Dendrite Announces Third Quarter Conference Call.

Business Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--Oct. 18, 2001

Dendrite (NASDAQ/NMS: DRTE) today announced that it would release its third quarter earnings after the close of the market Tuesday, October 23, 2001. A press release will be issued at 4 p.m. EST on that date, followed by a conference call at 4:30 p.m.

Dial-in information for the call is posted on the company's website, www.dendrite.com. In addition to the call, a link to a live simulcast will be available on the website. Replay information will also be available through the website following the completed call.

Dendrite also announced that it would hold an investment community briefing November 13 at 3 p.m. at the New York Palace, 455 Madison Avenue, New York City, led by John Bailye, Chairman and Chief Executive Officer, Paul Zaffaroni, President and Chief Operating Officer, and George Robson, Executive Vice President and Chief Financial Officer.

The meeting will include a discussion of issues affecting Dendrite's markets, recent changes in the competitive environment, and management's outlook for the business. Dendrite will detail its strategy for new products and services together with the anticipated impact on the financial model. An opportunity for informal sessions with senior management will follow the formal presentation.

This meeting will be particularly useful for investment professionals interested in pharmaceutical sales force automation, customer relationship management, and analytics. To register, call 973-425-2412 or email [e-mail].

About Dendrite

Dendrite, the visionary innovator in global pharmaceutical technology, helps clients strategically manage customer relationships to increase market share. The company creates unique, analytically driven solutions that enable pharmaceutical companies to influence prescriber behavior, thereby delivering a sustained competitive advantage. More than 80,000 pharmaceutical sales representatives and their managers from over 150 companies and 57 countries use Dendrite products and services. They represent 19 of the top 20 pharmaceutical companies. For more information, visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc. The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including: risks associated with and dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy selling cycles, product implementation cycles, customer budget cycles, and timing of revenue recognition; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; retention of key senior managers; and unique characteristics of the consumer packaged goods industry. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.